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Abstract
Introduction: Hepatitis C virus (HCV) is a significant 
problem for patients undergoing hemodialysis (HD) 
treatment. This medical problem has never been studied 
in Al Gharbiyah Governorate; this study was conducted 
aiming to estimate the prevalence of anti-HCV positive 
patients and the incidence of seroconversion in its 
different HD units.
Methods:  All 2351 patients maintained on HD in 
the eight towns of Al Gharbiyah Governorate were 
interviewed and their anti-HCV status was tested by a 
third-generation enzyme immunoassay. Patients who 
tested negative for anti-HCV at the start of the study 
were re-assessed monthly for HCV seroconversion and 
at the end of the study all patients were screened for HCV 
antibodies.
Results: At the start of our study in March 2011, we 
found that 824 out of  2351 patients (35%) were anti-HCV 
reactive. At the end of study in November 2011, we 
found that HCV seroconversion occurred in 168 out of 
1527 patients (11%) who were HCV free at the start of 
the study. By the end of the study, a total of 42.2% were 
found to be anti-HCV reactive. 
Conclusion: The study demonstrated high prevalence 
of anti-HCV in HD units in Al Gharbiyah Governorate. 
Similar studies must be conducted in all Egyptian 
governorates’ HD units to evaluate this major health 
problem all over Egypt. We also encourage strict 
application of preventive strategies for HCV infection in 
all health institutes, especially HD units.
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Introduction
Chronic kidney disease (CKD) has become a major public 
health problem worldwide over the past decades. This is 
probably due to the increased prevalence of hypertension, 
diabetes mellitus, and other risk factors for CKD in most 
countries [1]. Hepatitis C virus (HCV) infection is the 
most common chronic blood-borne infection. More than 
170 million people worldwide are chronically infected 
with the virus; HCV is responsible for over one million 
patients’ deaths from cirrhosis and liver cancer every year 
[2]. The prevalence of HCV infection in maintenance 
hemodialysis (HD) patients substantially exceeds that in 
the general population. HD patients have an increased 
risk of exposure to HCV infection. Several risk factors 
are suggested to be related to HCV dissemination in HD 
centers. Repeated blood transfusions, shared dialysis 
machines, surgery, nosocomial route and multi-dose drug 
injections are the major suggested routes [3]. However, 
studies have shown that de novo infections in single HD 
units may still occur in the absence of other parenteral 
risk factors [4, 5]. Partial immunosuppression found 
in HD patients, resulting in a poor antibody response, 
may play a role in increasing their susceptibility to the 
infection [4].
The natural course of HCV in HD patients is not well 
understood. It seems to differ from that in other HCV 
infected patients [6]. In HD patients, HCV infection has 
been associated with higher morbidity and mortality 
rates, and the management of these infections among 
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CKD patients with specific antiviral agents is associated 
with high rates of adverse effect [7-9]. 
The prevalence of HCV infection among HD patients 
varies from one country to the other and from one center 
or unit to the other. The reported prevalence of HCV 
infection among dialysis patients in developed countries 
ranges from 3.6 to 20%; it is much higher in developing 
countries [10]. Although anti-HCV positivity by EIA 
does not discriminate between patients with HCV viremia 
and those who had cleared the virus, it is very sensitive 
and may occasionally identify HD patients with very 
low viremia not detected by PCR. Since our goal was to 
assess the prevalence of infection rather than viremia, we 
considered EIA a suitable screening method [4].
Egypt has the largest epidemic for hepatitis C virus 
worldwide [11]. It is important to know the prevalence of 
HCV infection in each HD unit. This common medical 
problem has never been systematically studied in Al 
Gharbiyah Governorate. The aim of this study was to 
estimate the prevalence and the rate of seroconversion 
to anti- HCV positivity for patients in all HD units in Al 
Gharbiyah Governorate area of Egypt.  
Methods
All HD units in the eight towns of Al Gharbiyah 
Governorate including private and public units were 
included in this study. During the period from April 
2011 to November 2011, we collected data from 2351 
patients, including their reported HCV antibody status at 
the start of HD. Serologic tests for detection of anti-HCV 
were performed monthly throughout the study using 
third generation micro-particle enzyme immunoassays 
(MEIA) (Axsym® HCV, version 3.0, Abbott, Wiesbaden, 
Germany). All patients confirmed to carry anti-HCV by 
repeated tests on new blood samples were considered 
positive. All anti-HCV positive patients were referred 
to hepatology service. Permission to conduct the study 
was obtained from the technical directors of each unit 
involved. This protocol was approved by the institutional 
human research ethical committee (IHREC) of  the faculty 
of medicine, Tanta University. An informed consent was 
obtained from all patients before they participated in the 
study. Statistical analyses were conducted using SPSS 
version 13.
Results
This study involved 2351 patients treated with HD and 
screened for anti-HCV antibodies. The mean age of the 
patients was 52±11 years (age rang15-75 years). 1406 
were male (61%). At entry of the study in March 2011, 
we found that 824 out of 2351(35%) were anti-HCV 
reactive. At the end of our study in November 2011, we 
found that HCV seroconversion occurred in 168 out of 
1527 patients who were seronegative at the start of the 
study (11%). At the end of the study, a total of 42.2% 
were found to be anti-HCV reactive. 
Discussion
The reported prevalence of HCV infection among dialysis 
patients in developed countries ranges from 3.6 to 20% 
[10]. Prevalence rates are somewhat higher in other parts 
of the world, particularly in Egypt and Saudi Arabia [12, 
13]. The purpose of our work was to provide accurate 
prevalence and discuss HCV infection in HD units in Al 
Gharbiyah Governorate.
We found that the overall prevalence of HCV-Ab was 
35% in all HD patients in Al Gharbiyah Governorate in 
March 2011. This high prevalence may be due to repeated 
blood transfusions, shared dialysis machines, surgery, 
nosocomial route, and multi-dose drug vials. This agrees 
with previous reported studies, which show significant 
increase in HCV antibody positivity in patients subjected 
to multiple blood transfusions and having prolonged 
duration of HD [14, 15]. Our findings also show a high 
HCV seroconversion rate (11%) among patients who 
were HCV-free at the start of the study. Seroconversion 
may be associated with previous blood transfusion, 
central venous catheter use, switching between dialysis 
places, improper implementation of isolation procedures 
and infection control measures.
The Center for Disease Control does not currently 
recommend dedicated machines, patient isolation or a ban 
on reprocessing of dialyzers for HCV positive patients 
[15]. Hemodialysis units should focus on implementation 
of, and adherence to, strict infection-control procedures 
designed to prevent transmission of blood-borne 
pathogens, including HCV and other infectious diseases. 
Decreasing the infection risk with careful screening, 
prophylactic measures, and vaccination when it becomes 
available should improve patient morbidity and reduce 
associated costs. 
Conclusion 
 HCV is prevalent in HD patients in this study with a high 
rate of positive seroconversion. We encourage similar 
studies to be conducted in all Egyptian governorates 
to evaluate this major health problem all over Egypt. 
We also suggest that regular audits of infection-control 
procedures be included in performance reviews of HD 
units.
Editor notes
This short communication provides information on 
the prevalence of HCV infection among hemodialysis 
patients in one of the Egyptian governorates. The overall 
prevalence of  HCV antibody positivity was 35% and 
the six-month seroconversion rate was 11%. In this 
study, data about the average duration on hemodialysis 
at inception is missing, but in the majority of Egyptian 
studies the average duration of hemodialysis is around 
five years. Since there is no reason to think that the 
studied governorate is different, the prevalence rate 
with the given seroconversion rate of 11% is expected 
to be much higher than 35%. 
Assem El-sherif, Associate Editor 
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